IL-22: a promising candidate to inhibit viral-induced liver disease progression and hepatocellular carcinoma

Tumor Biology

Volumn 37, Issue 1, 2016, Pages 105-114

  Saalim, Muhammad ^a   Resham, Saleha ^a   Manzoor, Sobia ^a   Ahmad, Hassam ^b   Jaleel, Shahla ^b   Ashraf, Javed ^c   Imran, Muhammad ^a   Naseem, Sidrah ^a  

^a NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

^b Shaikh Zayd Hospital   (Pakistan)

^c Islam Dental College   (Pakistan)

Author keywords

Hepatocellular carcinoma; IL 22; Liver regeneration

Indexed keywords

EPIDERMAL GROWTH FACTOR; HEPATITIS B VIRUS PROTEIN; HEPATITIS C VIRUS PROTEIN; INSULIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 6; JANUS KINASE; NORADRENALIN; SCATTER FACTOR; STAT PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS PROTEIN; CYTOKINE; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; STAT3 PROTEIN, HUMAN;

CANCER INHIBITION; ENZYME ACTIVATION; HUMAN; INTRACELLULAR SIGNALING; LIGAND BINDING; LIVER CELL CARCINOMA; LIVER PROTECTION; LIVER REGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; VIRUS HEPATITIS; VIRUS INHIBITION; ANIMAL; BIOLOGICAL MODEL; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE COURSE; HEPACIVIRUS; HEPATITIS B VIRUS; INFLAMMATION; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; REGENERATION; SIGNAL TRANSDUCTION; VIROLOGY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINES; DISEASE PROGRESSION; HEPACIVIRUS; HEPATITIS B VIRUS; HUMANS; INFLAMMATION; INTERLEUKINS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER REGENERATION; MODELS, BIOLOGICAL; REGENERATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84946422836     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4294-1     Document Type: Review

References (51)

1. Society AC. What are the key statistics about liver cancer? 2014. http://www.cancer.org/cancer/livercancer/detailedguide/liver-cancer-what-is-key-statistics.
2. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002;36(5):1206–13.
3. Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol. 2005;42(2):218–24.
4. Cougot D, Neuveut C, Buendia MA. HBV induced carcinogenesis. J Clin Virol. 2005;34:S75–S8.
5. Anthony P. Hepatocellular carcinoma: an overview. Histopathology. 2001;39(2):109–18.
6. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene. 2003;22(33):5093–107.
7. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature. 2005;436(7053):933–8.
8. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene. 2006;25(27):3834–47.
9. Rehermann B. Hepatitis C, virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009;119(7):1745–54.
10. Dumoutier L, Louahed J, Renauld J-C. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol. 2000;164(4):1814–9.
11. Radaeva S, Sun R, Pan H, Hong F, Gao B, Interleukin 22. (IL‐22) plays a protective role in T cell‐mediated murine hepatitis: IL‐22 is a survival factor for hepatocytes via STAT3 activation. Hepatology. 2004;39(5):1332–42.
12. Dumoutier L, de Meester C, Tavernier J, Renauld J-C. New activation modus of STAT3 a tyrosine-less region of the interleukin-22 receptor recruits STAT3 by interacting with its coiled-coil domain. J Biol Chem. 2009;284(39):26377–84.
13. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004;117(8):1281–3.
14. Bromberg J, Darnell Jr JE. The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2000;19(21):2468–73.
15. Yoshida T, Hanada T, Tokuhisa T, Kosai K-I, Sata M, Kohara M. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med. 2002;196(5):641–53.
16. Gao B. Cytokines, STATs and liver disease. Cell Mol Immunol. 2005;2(2):92–100.
17. Michalopoulos GK, DeFrances MC. Liver regeneration. Science. 1997;276(5309):60–6.
18. Wang H, Lafdil F, Kong X, Gao B. Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target. Int J Biol Sci. 2011;7(5):536.
19. Nagem RAP, Colau D, Dumoutier L, Renauld J-C, Ogata C, Polikarpov I. Crystal structure of recombinant human interleukin-22. Structure. 2002;10(8):1051–62.
20. de Oliveira NM, Ferreira Jr JR, Colau D, Fischer H, Nascimento AS, Craievich AF, et al. Interleukin-22 forms dimers that are recognized by two interleukin-22R1 receptor chains. Biophys J. 2008;94(5):1754–65.
21. Foster RG, Golden-Mason L, Rutebemberwa A, Rosen HR. Interleukin (IL)-17/IL-22-producing T cells enriched within the liver of patients with chronic hepatitis C viral (HCV) infection. Dig Dis Sci. 2012;57(2):381–9.
22. Okuhara S, Umemura T, Joshita S, Shibata S, Kimura T, Morita S et al. Serum levels of interleukin‐22 and hepatitis B core‐related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B. Hepatology Research. 2014.
23. Dambacher J, Beigel F, Zitzmann K, Heeg MH, Göke B, Diepolder HM, et al. The role of interleukin-22 in hepatitis C virus infection. Cytokine. 2008;41(3):209–16.
24. Ki SH, Park O, Zheng M, Morales‐Ibanez O, Kolls JK, Bataller R, et al. Interleukin‐22 treatment ameliorates alcoholic liver injury in a murine model of chronic‐binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology. 2010;52(4):1291–300.
25. Støy S, Sandahl TD, Dige AK, Agnholt J, Rasmussen TK, Grønbæk H, et al. Highest frequencies of interleukin-22-producing T helper cells in alcoholic hepatitis patients with a favourable short-term course. PLoS One. 2013;8(1), e55101.
26. Ashour TH. Therapy with interleukin-22 alleviates hepatic injury and hemostasis dysregulation in rat model of acute liver failure. Advances in hematology. 2014; 2014.
27. Brault C, Lévy PL, Bartosch B. Hepatitis C virus-induced mitochondrial dysfunctions. Viruses. 2013;5(3):954–80.
28. Gurtsevitch V. Human oncogenic viruses: hepatitis B and hepatitis C viruses and their role in hepatocarcinogenesis. Biochem Mosc. 2008;73(5):504–13.
29. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6(9):674–87.
30. Kitaoka S, Shiota G, Kawasaki H. Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C. Hepato-Gastroenterology. 2002;50(53):1569–74.
31. Huang Y, Hwang S, Chan C, Wu J, Chao Y, Chang F, et al. Serum levels of cytokines in hepatitis C-related liver disease: a longitudinal study. Zhonghua yi xue za zhi = Chinese medical journal. Free China ed. 1999;62(6):327–33.
32. Sato T, Asanuma Y, Masaki Y, Sato Y, Hatakeyama Y, Kusano T, et al. Changes in tumor necrosis factor-a and interleukin-1 beta production following liver surgery on cirrhotic patients. Hepato-Gastroenterology. 1995;43(11):1148–53.
33. Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld J-C. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line pathways that are shared with and distinct from IL-10. J Biol Chem. 2002;277(37):33676–82.
34. Boniface K, Bernard F-X, Garcia M, Gurney AL, Lecron J-C, Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol. 2005;174(6):3695–702.
35. Wolk K, Witte E, Wallace E, Döcke WD, Kunz S, Asadullah K, et al. IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006;36(5):1309–23.
36. Pan H, Hong F, Radaeva S, Gao B. Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3. Cell Mol Immunol. 2004;1(1):43–9.
37. Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, Araki Y, et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology. 2005;129(3):969–84.
38. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity. 2007;27(4):647–59.
39. Park O, Wang H, Weng H, Feigenbaum L, Li H, Yin S, et al. In vivo consequences of liver‐specific interleukin‐22 expression in mice: implications for human liver disease progression. Hepatology. 2011;54(1):252–61.
40. Kong X, Feng D, Wang H, Hong F, Bertola A, Wang FS, et al. Interleukin‐22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology. 2012;56(3):1150–9.
41. Kong X, Feng D, Mathews S, Gao B. Hepatoprotective and anti‐fibrotic functions of interleukin‐22: therapeutic potential for the treatment of alcoholic liver disease. J Gastroenterol Hepatol. 2013;28(S1):56–60.
42. W-w X, M-j Z, Liu S, Xu T, Gao J, Wang J-x, et al. Hepatoprotective effects of IL-22 on fulminant hepatic failure induced by d-galactosamine and lipopolysaccharide in mice. Cytokine. 2011;56(2):174–9.
43. Liang SC, Nickerson-Nutter C, Pittman DD, Carrier Y, Goodwin DG, Shields KM, et al. IL-22 induces an acute-phase response. J Immunol. 2010;185(9):5531–8.
44. Ho HH, Ivashkiv LB. Role of STAT3 in type I interferon responses negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem. 2006;281(20):14111–8.
45. Zhang Y, Ji H, Liu Y, Shen X, Gao F, Fong C et al., editors. The immunomodulatory role of IL-22 in mouse liver ischemia and reperfusion injury (IRI): enhancement of autophagy by STAT3-c-myc signaling. American Journal of Transplantation; 2013: Wiley-Blackwell 111 River ST, Hoboken 07030-5774, NJ USA.
46. Zhao J, Zhang Z, Luan Y, Zou Z, Sun Y, Li Y, et al. Pathological functions of interleukin‐22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology. 2014;59(4):1331–42.
47. Zhang Y, Cobleigh MA, Lian JQ, Huang CX, Booth CJ, Bai XF, et al. A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology. 2011;141(5):1897–906.
48. Chestovich PJ, Uchida Y, Chang W, Ajalat M, Lassman C, Sabat R, et al. IL-22: implications for liver ischemia/reperfusion injury. Transplantation. 2012;93(5):485.
49. Feng D, Wang Y, Wang H, Weng H, Kong X, Martin-Murphy BV, et al. Acute and chronic effects of IL-22 on acetaminophen-induced liver injury. J Immunol. 2014;193(5):2512–8.
50. Zhang Z, Zhao J, Fu Y, Wang F-S. Increased IL-22-producing cells contribute to liver fibrosis through promoting Th17 migration in chronic HBV patients (P3363). The Journal of Immunology. 2013;190 (meeting abstracts 1):202.4.
51. Jiang R, Tan Z, Deng L, Chen Y, Xia Y, Gao Y, et al. Interleukin‐22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology. 2011;54(3):900–9.